Oil, Rates and the Quality of the AI Boom

2. Complete macro-event table

Rank	Event	Exact time	Actual vs consensus/prior	Surprise	First reaction	Why it mattered
1	U.S.–Iran/Hormuz impasse	Iran Monday premarket; Trump during U.S. session	No forecast	Oil-bullish/inflationary	Brent +5%; 10Y +5 bp; S&P -0.1%; European gas ~+8%	Energy, inflation, central-bank and geopolitical risk
2	China July CPI/PPI	Aug. 9, 09:30 CST / Aug. 8, 21:30 EDT; first cash reaction Aug. 10 Asia	CPI 0.5% y/y vs 0.8%, 1.0% prior; -0.1% m/m vs +0.2%, -0.3%. PPI 3.5% y/y vs 3.8%, 4.1%; -0.7% m/m vs -0.3%	Downside ~0.3 pp y/y	Shanghai +0.67%; CSI 300 +0.16%; China 10Y -~0.4 bp; CNH ~0.04% weaker	China demand, commodities, PBOC easing

There were no qualifying scheduled U.S. releases or Fed decisions/speeches Monday. Routine bill auctions are retained only in the audit.

3. Detailed macro events and opinion clusters

Hormuz / U.S.–Iran impasse

Facts. Iran said reopening required ending the blockade, sanctions relief, frozen assets and compensation. The Oman framework was a temporary lane, not necessarily full reopening. Trump rejected reparations and retained “massive escalation.” The SPR fell 6.1 million barrels to 298.7 million, lowest since 1983. (Axios, AP, EIA)

• “Strategic lever, not toll dispute.” Mostafa Najafi, Abdolreza Davari, Rahman Ghahremanpour; ISW: Iran seeks security authority and navigation leverage. Six conditions, the separation of temporary lanes, hardliner Mohsen Rezaei's appointment and halted Kharg loadings support it. Implication/horizon: persistent oil/LNG/freight premium for weeks to months. Risk: Iran's own export stress or face-saving bargain. Confidence: high near term, medium beyond weeks. (AP, Aug. 8)
• “Pressure can force a workaround.” David Schenker/Washington Institute; Mohammad Javad Zarif: rising costs and Oman's lane create an opening. Implication: a signed pact could remove several dollars of oil premium in days. Risk: Monday's mutual demands. Confidence: medium-low. (AP, Aug. 7)
• “Domestic optics favor stalemate.” Eliot Cohen; Mahdi Mohammadi: concessions are hard for either government to sell. Implication: recurring escalation and volatility. Disconfirming evidence: deliberately ambiguous face-saving language. Confidence: medium-high. (AP)
• “Physical tightness underpriced.” Eric Nuttall/Ninepoint, via secondary summary: restricted flows/depleted buffers imply crude should stay at least $10 above prewar levels. Implication: 1–3 month upside for producers; pressure on duration. Risks: inventories, weak demand, higher flows, OPEC. Confidence: medium-low because original BNN transcript was inaccessible. (Secondary summary)

Consensus: unconditional reopening is not the base case. Disagreement: compromise before physical tightness worsens. Resolvers: signed terms, tanker/insurance data, Kharg loadings, U.S. concessions, EIA stocks/SPR and military activity.

China July CPI/PPI

Facts. Gasoline fell 10.7% m/m and oil extraction 11.8%; core CPI stayed +0.9% y/y. NBS attributed PPI weakness to oil, refined products, chemicals, metals and seasonal construction. (NBS explanation, Reuters syndication)

• “Oil shock fading; PPI peaked.” Lynn Song/ING; Chen Xinquan/Goldman via SCMP; Zhaopeng Xing/ANZ; NBS: July was energy normalization, not collapse. Implication: less upstream pressure/more room for duration over 1–2 quarters. Risk: renewed Hormuz shock or fiscal surge. Confidence: high for July, medium-high on durability. (ING, SCMP)
• “Weak demand raises easing odds.” Song/ING; Zhiwei Zhang/Pinpoint; Xing/ANZ: three negative monthly CPI prints, soft food/rent and PMIs show insufficient demand; ING expects a 10 bp PBOC cut. Implication: lower yields/softer CNY, policy-sensitive equity support, weak pricing power. Risk: resilient services/core inflation. Confidence: medium-high. (Reuters syndication)
• “Reflation dented, not dead.” Song/ING; Xing/ANZ; NBS: core/services/tech pockets remain positive and PPI is still +3.5%. Implication: measured rather than crisis easing. Risk: property/jobs deterioration or core below zero. Confidence: medium.

Consensus: fading energy plus weak demand; PPI likely peaked. Disagreement: normalization versus renewed broad deflation. Resolvers: core breadth, rents/property, pork, non-energy PPI, PMIs/credit, fiscal implementation and PBOC action.

4. Complete earnings/call table

Rank	Company	Release / call (ET)	Key actual vs consensus	Critical update	Reaction
1	Barrick (B)	6:00 / 11:00 a.m.	Adj EPS $0.82 broadly inline; rev $5.292B vs $5.10B	Fourmile/NGM deal; capex lowered on Reko Diq delay	-6.34%
2	Rocket Lab (RKLB)	4:05 / 5:00 p.m.	Rev $234.1M vs $231.6M; EPS -$0.08 vs -$0.06	Q3 lower GM; Neutron Q4 pad delivery/window narrowing	-3.37%; -1.8% AH
3	Hims (HIMS)	after close / 5:00 p.m.	Rev $753.2M vs ~$700M; EPS -$0.37 vs -$0.03 to -$0.05	Revenue raised; EBITDA ceiling/margin lowered	+0.7%; -5.6% AH
4	monday.com (MNDY)	7:00 / 8:30 a.m.	Rev $364.6M vs $355.0M; EPS $1.48 vs $1.11	Q3 rev light; FY rev held, margin raised	-4.84%
5	JBS	1:11 p.m. filing / Aug. 11 call	Rev $23.90B vs $23.03B; adj EPS $0.20 vs $0.31	Margin compression; CEO handoff; Indonesia JV	-5.66%; -1.7% AH
6	AAON	7:00 a.m. / 5:00 p.m.	Rev $627.0M vs $508.8M; EPS $0.69 vs $0.51	Sales raised; GM cut 200 bp	-5.89%
7	Embraer (EMBJ)	6:19 / 8:00 a.m.	Rev $2.235B vs $2.05B; GAAP ADS EPS $1.188 vs ~$0.61	Margin raise mostly tax/tariff; FCF doubled	+1.08% after +9.25%
8	AST SpaceMobile	4:39 / 5:00 p.m.	Rev $31.5M vs $34.3–35.0M; GAAP EPS -$0.77 vs -$0.32	Backlog $1.3B; ~45 satellites early 2027	-4.39%; -1.0% AH
9	Upwork	4:46 / 5:00 p.m.	Rev $191.7M essentially inline; EPS $0.41 vs $0.34–0.35	FY revenue/EBITDA/EPS sharply cut	-20.25% AH
10	Archer	filings 4:06 a.m.–1:04 p.m. / 5:00 p.m.	Rev $5.0M; EPS -$0.34 inline	Acquiring Wisk/Insitu/SkyGrid; Boeing stake	+12.0%
11	RIOT	4:22 p.m. filing / evening call	Rev $174M vs ~$150M; EPS -$0.68 vs -$0.39	20-year 191 MW AI lease; $9.1B base revenue	-5.46%; +25.26% AH
12	Babcock & Wilcox	4:26 / 5:00 p.m.	Rev $319.7M vs ~$197M; EPS $0.07 vs $0.02–0.03	Backlog $2.6B; turbine reservation	+40.5% AH
13	NIQ	4:06 / 5:00 p.m.	Rev $1.124B vs $1.10–1.12B; adj EPS $0.27 vs $0.20	Revenue/EPS/FCF raised	+17.95% AH
14	Ferguson	6:45 / 8:30 a.m.	Rev $8.751B vs $8.61B; EPS $3.39 vs $3.30	Sales/margin guide raised	+2.76%
15	Alcon	4:31 p.m. / Aug. 11 call	Rev $2.782B vs $2.77B; core EPS $0.84 vs $0.75–0.76	Margin/EPS guide raised	+2.4% AH
16	Axsome	7:05 / 8:00 a.m.	Rev $218.4M vs $220.9–225.1M; EPS -$0.99 vs -$0.86 to -$0.89	AUVELITY ≥65 NBRx +126%	+4.1% after -8%
17	BridgeBio	4:04 / 4:30 p.m.	Rev $243.7M vs ~$221M; EPS -$0.78 vs -$0.58 to -$0.63	Attruby $222.4M; three NDAs	+0.2%; +2.7% AH
18	Simon Property	4:08 / 5:00 p.m.	RE FFO $3.29 vs $3.18; rev $1.791B vs $1.71B	FY RE FFO raised	-1.06%; flat AH
19	AECOM	after close / Aug. 11 call	Ex-charge EPS $1.49 vs $1.46; $337M charge	FCF cut to ~$300M	-3.7%; +0.4% AH
20	Camtek	7:16 / 9:00 a.m.	Rev $133.2M vs $132.8M; EPS $0.78 vs $0.77	H2 >30% above H1; >$600M orders	+1.77%
21	RadNet	Aug. 9 / Aug. 10 10:30 a.m.	Rev $622.7M vs ~$610M; EPS $0.29 vs $0.18–0.20	Guide raised; AI ARR >$140M target	+7.04%

5. Detailed company sections with opinion clusters

1. Barrick Mining (B)

Facts/call. Adjusted EPS $0.82 was broadly inline across provider estimates ($0.81–0.83); revenue $5.292B beat MarketBeat's $5.10B. Gold production 796koz exceeded company quarterly guidance; AISC $1,866/oz and attributable FCF only $141M. Barrick contributes Fourmile to NGM while Newmont contributes Mike/Fiberline and pays $1.95B; management valued the full package near $4B but would not decompose it. (Release, transcript)

• “Fourmile giveaway fear.” Anita Soni/CIBC explicitly linked the decline to the lack of a technical valuation barometer; Josh Wolfson/RBC, Daniel Major/UBS and Tanya Jakusconek/Scotia pressed for the missing bridge. Implication: overhang through the IPO/prospectus; risk: $1.95B is only equalization, with assets/litigation/IPO consent also valuable. Confidence: high on cause, medium-low on underlying economics.
• “Paying for alignment unlocks synergies.” Lawson Winder/BofA and Steve Green/TD focused on faster Fourmile development/processing; Scotia/RBC on IPO structure. Implication: multi-year operating and multiple upside. Risks: new processing capex, permits, and only ~10% initial IPO float. Confidence: medium.
• “Operations improve, ramp risk remains.” Winder/BofA, Bennett Moore/JPM; RBC pre-result baseline: production beat and guidance held, but costs, weak FCF and sequential Q3/Q4 ramp remain. Confidence: medium-high.

Consensus: solid operating quarter overwhelmed by transaction opacity. Disagreement: concession versus rational payment for alignment. Resolvers: transaction schedules, NewCo prospectus/valuation, Fourmile technical work, processing plan, Q3/Q4 delivery and Reko Diq reset.

2. Rocket Lab (RKLB)

Facts/call. Revenue $234.1M beat by 1.1%; EPS -$0.08 missed by $0.02. Backlog reached $2.36B (+137%), adjusted EBITDA loss $8.8M beat company guidance, but Q3 guides to lower gross margin and $17–23M EBITDA loss. Q2 FCF use was $110.1M; liquidity near $2.4B largely reflects a $1.08B ATM. Management now says Neutron production aligns with Q4 pad delivery and the 2026 launch window is “narrowing.” (Release, transcript)

• “Integrated space-prime demand.” Management/market inference; no same-day sell-side note: >$1B of recent bookings, 90+ launches and defense/GEO awards validate the build-launch-operate model. Horizon: 6–24 months. Risks: options/timing, platform mix, integration. Confidence: high facts, medium-high implication.
• “Neutron slip.” Eric Berger/Ars Technica: softer wording effectively concedes 2027. Implication: revenue/EBITDA/FCF pivots move right. Disconfirming evidence: management still hopes for 2026 and hardware is progressing. Confidence: high that language softened, medium on launch year.
• “Quality-of-beat/cash caution.” Inference: small beat, EPS miss, lower Q3 margin and equity-funded liquidity explain the selloff. Risk to bear case: Q2 gross margin/EBITDA execution was far above guide. Confidence: medium-high.

Consensus: exceptional demand, but Neutron timing/margins/cash dominate. Disagreement: conservative wording versus de facto slip. Resolvers: tank qualification/pad delivery, integrated test/FAA date, Q3 cash and Iridium approvals/financing.

3. Hims & Hers (HIMS)

Facts/call. Revenue $753.2M beat ~$700M and grew 38%; EPS -$0.37 missed -$0.03 to -$0.05. Subscribers reached 2.891M (+19%); U.S. revenue reaccelerated to +16% and international rose 17-fold, including Eucalyptus. FY revenue rose to $3.1–3.3B, but EBITDA narrowed to $275–325M from $275–350M; gross margin was 64% and FCF -$68.2M. (Release, transcript)

• “Subscriber/GLP-1 flywheel.” Management/market inference; no same-day named note: branded weight-loss cohorts and TRT cross-sell support 2–6 quarter U.S. acceleration. Risks: retention unquantified and mix effects. Confidence: medium-high.
• “Revenue quality and cash bear.” Inference, reflected in Evercore's Mark Mahaney questioning the lower EBITDA ceiling: EPS miss, 64% GM, negative FCF and lower implied margin suggest branded-drug resale/international dilute economics. Disconfirmers: EBITDA beat quarterly guide and management expects H2 FCF positivity. Confidence: high.
• “International platform versus integration.” Needham's Ryan MacDonald and Barclays' Glen Santangelo questioned cross-sell/profitability: ≥$600M international revenue is a channel asset, but contribution stays near break-even. Horizon: 1–3 years. Confidence: medium.

Consensus: top-line reacceleration is real; investors objected to its cost/quality. Disagreement: temporary acquisition spend versus structurally lower-margin mix. Resolvers: cohort retention/LTV, Q3/Q4 GM/FCF, Eucalyptus profitability, Novo economics and FDA/FTC milestones.

4. monday.com (MNDY)

Facts. Revenue $364.6M beat by 2.7%; non-GAAP EPS $1.48 beat by 33%. AI ARR doubled q/q and generated 17% of net-new ARR; >$100k customers +37%, >$500k +68%, RPO +34%. Q3 revenue $368–370M was ~0.9% below consensus and only +16–17%; NDR eased to 109%. FY revenue/FCF held while restructuring raised operating-margin guidance. (SEC release)

• “AI/upmarket compounding.” Jefferies pre-result baseline: enterprise and AI indicators can sustain 20%+ growth. Evidence: AI net-new contribution and large-customer/RPO growth. Risk: undisclosed AI dollar base, NDR drift and Q3 deceleration. Confidence: medium.
• “Transition masks slowing core.” UBS pre-result baseline: NDR slippage, seat-to-credit uncertainty and deceleration matter more than the beat. Implication: SaaS multiple remains hostage to forward growth. Disconfirming evidence: cRPO +27% and record enterprise adds. Confidence: medium-high.
• “Margin reset, not demand acceleration.” Inference: workforce cuts drive the profit raise while revenue/FCF are unchanged. Confidence: high mechanics, medium sector read-through.

Consensus: strong quarter and AI indicators, but no proven reacceleration. Disagreement: AI consumption offsetting seat pressure versus restructuring masking slower core. Resolvers: AI ARR dollars, NDR, Q3 midpoint delivery and post-restructuring 2027 growth.

5. JBS (JBS)

Facts. Revenue $23.900B beat by ~3.8%; adjusted EPS $0.20 missed $0.31 and EBITDA margin fell to 6.0% from 8.4%. Beef North America remained loss-making (-1.0% margin), while every profitable IFRS segment compressed. Leverage rose to 3.1x. Wesley Batista Filho becomes CEO in January; a Danantara JV will invest $2.5B for 25% of Australia/NZ. Call is Aug. 11. (10-Q, release)

• “Cycle trough plus self-help.” BMO, Bradesco BBI, Morgan Stanley pre-result: 2026 is the earnings trough and plant rationalization/diversification cushions it. Evidence: beef loss narrowed and revenue record. Risk: all profitable segments compressed. Confidence: medium.
• “Balance sheet dominates.” Barclays and BofA pre-result: capex/dividend flexibility depends on leverage below 3x. Q2 at 3.1x validates concern. Implication: capped capital returns until deleveraging. Disconfirming: positive FCF and $7.7B liquidity. Confidence: medium-high.
• “Sticky beef inflation; substitution caps breadth.” Inference: cattle scarcity sustains beef pricing/cost pressure, but cheaper poultry/pork limits broad protein inflation. Horizon: 1–4 quarters. Confidence: medium.

Consensus: weak cycle buffered by diversification, but EPS/leverage negative. Disagreement: trough now versus extended cattle/poultry downcycle. Resolvers: Aug. 11 call, cattle/import data, Q3 margins, leverage/FCF and JV close.

6. AAON (AAON)

Facts/call. Revenue $627.0M beat by 23%; adjusted EPS $0.69 beat by 35%. BASX sales +216%, liquid cooling +208%, backlog $1.97B (+98%), but BASX backlog fell 11.7% q/q. FY sales growth rose to 55–60%, while gross-margin guidance fell to 25–26% from 27–28%; Q2 GM fell 230 bp. (Release, transcript)

• “Demand/throughput inflection.” Management/market inference: data-center cooling and core HVAC share gains are real through 2027–28. Risk: lower sequential BASX backlog and no current-quarter bookings disclosure. Confidence: high facts, medium-high implication.
• “Earnings quality trails optics.” Inference; multiple call analysts pressed bookings/margins: 200 bp guide cut, mix and price-cost lag explain the -5.9% move. Disconfirming: ex-Memphis Oklahoma GM +70 bp and BASX GM +210 bp. Confidence: high.
• “Premium valuation already reflects demand.” David Tarantino/KeyBanc pre-result: compelling long-run growth but investment needs and valuation limit upside. Confidence: medium.

Consensus: exceptional demand, but margin conversion/bookings cadence gate estimates. Disagreement: temporary ramp versus structurally capital-intensive/lower-margin growth. Resolvers: Q3 bookings, Q4 margin/price-cost, Memphis absorption, ACP margin and FCF.

7. Embraer (EMBJ)

Facts/call. Revenue $2.235B beat by ~9%; GAAP ADS EPS $1.188 versus ~$0.61; backlog $34.5B and FCF $401M. EBIT-margin guidance rose to 10.0–10.6% and FCF to ≥$400M. Yet $106M of the ~$110M midpoint EBIT lift came from a tax credit and direct-tariff exemption. Commercial margin fell to 2.9%. (Primary filing)

• “Production smoothing/backlog.” Lucas Barbosa, Victor Tani and Gabriel Tinem/Santander pre-result: 65 deliveries show better production leveling and cash predictability. Implication: positive 6–18 month aerospace/defense/MRO demand. Risks: supply chain and prepayment-driven cash. Confidence: medium-high.
• “Margin rerating real, but smaller.” BTG Pactual pre-result: recurring margin recovery supports rerating; underlying consolidated margin still exceeded the old range. Counterevidence: 125 bp of the 130-bp guide-midpoint rise was tax/tariff. Confidence: medium.
• “Giveback signals earnings-quality disagreement.” Inference: +9.25% high faded to +1.08% as one-offs were digested. Confidence: high observation, medium cause.

Consensus: strong demand/delivery and higher estimates. Disagreement: durable operating improvement versus one-off-heavy guide. Resolvers: H2 Commercial margin, recurring FCF, deliveries and 2027 tariff treatment.

8. AST SpaceMobile (ASTS)

Facts/call. Revenue $31.5M missed by 8–10%; GAAP EPS -$0.77 included a $125.9M BlueBird 7 write-off. FY revenue $150–200M was held; backlog rose to $1.3B. Cash/restricted cash was $2.7B and >$3.7B pro forma. Thirteen satellites are in orbit; BB14–16 ship shortly, 17–46 are in production and ~45 satellites are targeted in early 2027. (Release, transcript)

• “Government/backlog bridges commercial timing.” Scott Searle/Roth pre-result: government/gateway revenue can support the ramp before full service. Evidence: >$100M funded awards, J-LEO potential and $1.3B backlog. Risk: award recognition and backlog composition. Confidence: medium.
• “Execution clock dominates.” Inference; BofA/Cantor/William Blair call questions centered here: the steep H2 revenue requirement and early-2027 45-satellite target make launch cadence decisive. Confidence: high risk identification, medium downside magnitude.
• “Liquidity buys optionality at high spend.” Inference: >$3.7B funds scale, but Q2 capex was $610M and Q3 guides $350–425M. Confidence: high.

Consensus: platform/demand strengthened, but launch/revenue timing rules valuation. Disagreement: government/gateway bridge versus another right-shift. Resolvers: BB14–16 launches, monthly cadence, beta service, Q3/Q4 revenue, awards/J-LEO and gateway acceptance.

9. Upwork (UPWK)

Facts. Revenue $191.7M was essentially in line across providers; adjusted EPS $0.41 beat $0.34–0.35 and EBITDA margin reached 33%. Yet GSV fell 3.6%, active clients 4%, CFO 35% and FCF 45%. FY revenue was cut to $730–750M from $760–790M, EBITDA to $225–235M from $250–260M, and EPS to $1.38–1.43 from $1.50–1.55. (SEC release, 10-Q)

• “Higher-value AI survivor platform.” Management plus bullish pre-result baselines: AI Strategy Consulting +50%, Business Plus GSV +174%, record GSV/client and EOR +29% support a 12–24 month mix recovery. Risk: small/undisclosed bases while totals shrink. Confidence: medium on operations, low-medium on commercial scale.
• “AI substitution overwhelms near term.” Brad Erickson/RBC pre-result: automation and SMB pressure can remove core GSV faster than new categories grow. Q2's client/GSV contraction, AI growth slowing to +22% and guide cut corroborate it. Implication: negative 2026 freelance-platform read-through. Risk: enterprise/AI acceleration. Confidence: high near term, medium long term.
• “Cost discipline masks demand/cash decline.” Inference: 33% margin and EPS beat coexist with deep guide/FCF cuts after workforce reduction. Confidence: high mechanics, medium valuation.

Consensus: profitable and higher-value work is real, but core shrinkage dominates. Disagreement: AI expands the category versus substitutes the lower end. Resolvers: clients/GSV, absolute AI dollars, Business Plus/Lifted scale, Q3 midpoint and FCF.

10. Archer Aviation (ACHR)

Facts. GAAP EPS -$0.34 matched consensus; adjusted EBITDA loss $177.1M was near the low end of guide, with Q3 again $170–200M. Cash/ST investments fell $215M q/q to $1.561B. Archer will acquire Boeing's Wisk, Insitu and SkyGrid for shares equal to 19.75% of pre-close Class A plus warrants; Boeing receives governance/technology rights. Insitu claims >$200M annual revenue and profitability, but audited target economics were not disclosed. (Earnings, transaction)

• “Transformational defense/autonomy platform.” Management and same-day tape; no independent same-day note: Insitu revenue/combat data, Wisk autonomy, SkyGrid/ZEE and Boeing validation diversify beyond pre-revenue passenger eVTOL. Horizon: 6–24 months. Risk: integration, undisclosed target margins. Confidence: high on assets, medium on synergy.
• “Validation with dilution/capital needs.” Primary economics; Noah Poponak/Goldman pre-event Neutral context: initial shares imply ~16.5% post-issue Class A before warrants/adjustments, and the equity backstop requires a ≥$400M raise. Implication: upside can be offset per share. Disconfirming: profitable Insitu and management's no-structural-burn-rise pledge. Confidence: high terms, medium valuation.
• “Certification still gates Midnight.” Poponak's timeline focus: city flights/eIPP matter, but no new FAA deadline or commercial-revenue guide. Confidence: medium.

Consensus: +12% move was strategic validation, not earnings surprise. Disagreement: platform value versus scope creep/dilution. Resolvers: close/final dilution, audited targets, consolidated burn, FAA milestones, eIPP launch and defense awards.

11. Riot Platforms (RIOT)

Facts/call. Revenue $174M beat a dated $150.5M estimate; EPS -$0.68 missed -$0.39, mostly through noncash BTC/D&A/impairment items. A frontier-AI-lab tenant signed a 191 MW, 20-year Rockdale lease worth $9.1B base revenue and estimated $7.3–8.2B NOI. Build cost is $2.1–2.3B; permanent financing and investment-grade backstop were not finalized. Combined with AMD, signed critical IT is 241 MW and contracted revenue $9.8B. (Release, transcript)

• “Powered-asset rerating.” Stephen Byrd/Morgan Stanley and John Todaro/Needham call framing: signed term/80–90% projected NOI validates miners with grid-secured AI sites. Horizon: multi-year. Risk: TCV is not NPV/cash today. Confidence: high contract, medium valuation.
• “Contract today, cash flow 2027–28.” Martin Toner/ATB, Byrd/MS, Brett Knoblauch/Cantor questions: debt/backstop unfinished and first 96 MW not due until Dec. 2027. Implication: construction, debt/dilution and tenant risk. Confidence: high facts, medium-high caution.
• “Corsicana option, not backlog.” Needham/Cantor: whole-site LOI could imply >$1B annual rent but is nonbinding. Confidence: high status, low-medium conversion.

Consensus: transformative validation; GAAP miss secondary. Disagreement: infrastructure valuation now versus awaiting tenant credit/financing/delivery. Resolvers: tenant/backstop identity, takeout loan, on-time capacity, realized NOI, binding Corsicana deal and equity/BTC funding.

12. Babcock & Wilcox (BW)

Facts/call. Revenue $319.7M rose 130% and beat a public ~$197M estimate by ~62%; EPS $0.07 beat $0.02–0.03 and was up from -$0.63. Adjusted EBITDA $21.8M rose 57% but margin compressed; backlog reached $2.569B (+533%). FY EBITDA was raised only at the high end to $80–105M. B&W reserved Siemens production rights for another 1 GW of steam turbines for one or two projects under negotiation; it is not yet a customer order. Cash rose mainly through $260M of equity proceeds, while 1H operating cash flow was only $0.4M. (Release, transcript)

• “Beat/raise validates conversion.” Management/tape with pre-event Craig-Hallum/Northland/Lake Street Buy baselines: a 62% revenue beat, positive EPS and Base ahead/on budget de-risk near-term backlog. Horizon: 6–18 months. Risk: EBITDA ceiling rose only $5M and margin compressed. Confidence: high facts, medium thesis.
• “Steam scarcity creates time-to-power option.” Rob Brown/Lake Street call framing: steam-first/combustion-later could shorten AI power delivery. Risks: reservation is not an order, pipeline is uncontracted and the claimed 3–5-year advantage is unverified. Confidence: medium.
• “Execution/capital intensity.” Aaron Spychalla/Craig-Hallum question framing plus 10-Q: skilled-labor issues already hurt one project; $1.49B backlog is beyond 2027 and liquidity is equity-funded. Disconfirming: debt payoff and Base schedule. Confidence: medium-high.

Consensus: Base execution and AI-power thesis were materially de-risked. Disagreement: imminent high-margin second project versus capital committed ahead of speculative demand. Resolvers: second full notice to proceed, Base site start, quarterly Base margin/cash, turbine terms, labor productivity and bond retirement.

13. NIQ (NIQ)

Facts/call. Revenue $1.124B grew 8% reported/5.8% organic cc, beating a $1.10–1.12B public range and company guide; adjusted EPS $0.27 beat $0.20, and EBITDA $261.9M beat the $242–246M guide. Operating cash flow swung to $140M from -$8.6M and levered FCF to $74M from -$63M. FY revenue, EPS and FCF guides rose; net leverage improved to 3.1x and <3x year-end was reiterated. AI-native revenue grew 34%, but management said the raised 2026 guide assumes no material AI contribution. (SEC release, transcript)

• “Execution/FCF inflection.” Stifel pre-result; Shlomo Rosenbaum/Stifel Q&A framing: organic growth, 270 bp margin expansion, EPS/EBITDA beat and positive FCF support a 6–12 month rerating. Risks: Q4 dependence and timing help. Confidence: high facts, medium-high thesis.
• “Proprietary data benefits from AI.” Stifel pre-view; JPMorgan/Needham/Wells Fargo/Baird Q&A: AI-native revenue +34%, data consumption +25% and 49 opportunities could open 2027+ budgets. Risks: no material 2026 guide contribution and experimental pricing. Confidence: medium.
• “Headline raise exceeds organic change.” Rosenbaum and Alexander Hess/JPMorgan framing: organic guide rose only 20–30 bp; FX/YiMian aid reported growth and fast product lines are smaller. Confidence: high.
• “Deleveraging unlock.” Rosenbaum/Curtis Nagle-BofA: Q2 FCF, H2 cash and 3.1x leverage support credit/equity upside. Risk: $3.1B net debt and B+ rating. Confidence: high.

Consensus: clean beat-and-raise rests on margin/cash/deleveraging more than AI. Disagreement: new AI budgets versus unproven monetization with mid-single-digit core growth. Resolvers: September Optiq launch, 49 opportunity conversions/pricing, NDR, H2 $300M FCF, <3x leverage and progress toward 30% margin.

14. Ferguson (FERG)

Facts/call. Revenue $8.751B beat $8.61B; adjusted EPS $3.39 beat $3.30. Organic growth was 3.8%; U.S. residential +2% and nonresidential +8%. Sales guidance rose to mid-single-digit and margin floor to 9.5%; gross margin still fell 20 bp and first-half operating cash flow fell. (SEC release)

• “Execution/guide outweigh margins.” No same-day named note; market inference: share gains and large projects support distributors over 2–4 quarters. Risk: weaker conversion/price-cost. Confidence: high facts, medium interpretation.
• “Share gains are not housing recovery.” Inference: management still called new build/RMI weak. Read-through: constructive for scale distribution, mixed for housing suppliers. Confidence: high.
• “M&A adds upside and execution risk.” Inference: $1.4B annualized YTD acquired revenue, higher capex and weaker working capital raise integration/leverage stakes. Confidence: medium-high.

Consensus: modest beat/raise, nonresidential strongest. Disagreement: share gains versus end-market recovery. Resolvers: Q3 organic growth, large-project conversion, RMI, margin floor and FloWorks economics.

15. Alcon (ALC)

Facts. Core EPS $0.84 beat $0.75–0.76; revenue $2.782B was 0.4% above consensus. Core margin expanded 160 bp cc. Implantables grew only 1% amid competition/soft cataract; PowerVision exit caused a $402M pre-tax noncash charge. Margin/EPS-growth guidance rose; the call is Aug. 11. (Release)

• “New-product operating leverage.” No same-day analyst note; inference: Unity +25% cc, ocular health +12%, margin and EPS raise support 6–12 month leverage. Risk: license revenue/tariff relief. Confidence: medium-high.
• “Uneven mix.” Ryan Zimmerman/BTIG prior call context: implantables remain below peers; sustained rerating needs premium-IOL share and consumables pull-through. Confidence: medium-high.
• “Prudent reset or weak R&D allocation.” Inference: ending PowerVision saves spend but questions acquisition discipline. Confidence: medium.

Consensus: positive profit quarter, revenue only inline. Disagreement: structural leverage versus one-time aids. Resolvers: Aug. 11 Q&A, Unity/PanOptix/Tryptyr data, cataract demand and tariff accounting.

16. Axsome (AXSM)

Facts/call. Revenue $218.4M missed by 1–3%; GAAP loss $0.99 missed most estimates. AUVELITY grew 51%, and new-to-brand prescriptions among patients ≥65 rose 126% after the agitation launch. SG&A rose 60%; cash was $319.9M and management says it funds to cash-flow positivity. (SEC release)

• “Leading indicators trump miss.” Management/market inference; no same-day named note: prescription acceleration and completed sales-force expansion support H2 AUVELITY. Risk: NBRx conversion/retention. Confidence: medium-high.
• “Spend/conversion caution.” Inference: revenue/EPS missed, SG&A surged, and SYMBRAVO scripts rose while revenue fell q/q. Disconfirming: launch spend can peak as revenue accelerates. Confidence: medium.
• “Pipeline optionality.” Inference: Q4 ENGAGE data and 2027 AXS-12 PDUFA matter more than the print. Confidence: medium.

Consensus: soft headline, strong commercial leading indicators. Disagreement: durable agitation step-up versus costly initial activity. Resolvers: Q3 paid scripts/net sales, SG&A, SYMBRAVO conversion and ENGAGE.

17. BridgeBio (BBIO)

Facts/call. Revenue $243.7M beat ~$221M; EPS -$0.78 missed -$0.58 to -$0.63. Attruby U.S. revenue $222.4M rose 23% q/q. Three NDAs were submitted; BBP-418 PDUFA is Nov. 27. Cash $720M excludes July's $1B preferred financing. (SEC release)

• “Rare-disease commercial platform.” Barclays and Morgan Stanley dated baselines: Attruby strength validates a multi-product franchise. Risk: gross-to-net, share and competition. Confidence: medium.
• “Three regulatory shots broaden value.” Same firms: 2026–27 decisions reduce single-asset concentration. Risks: review/label/uptake. Confidence: medium.
• “Spending/dilution counterweight.” Citi/Zacks cautious baselines plus inference: EPS miss, +43% operating costs and preferred financing matter. Confidence: low-medium.

Consensus: Attruby/regulatory progress outweighed EPS. Disagreement: launch slate outruns spending/financing. Resolvers: Oct. 8 Commercial Day, Q3 sales/gross-to-net, BBP-418 and later decisions.

18. Simon Property Group (SPG)

Facts/call. RE FFO $3.29 beat $3.18; revenue $1.791B beat $1.71B. Domestic NOI +8.5%, occupancy 96%, rent/sf +6.3% and retailer sales/sf +13.9%. FY RE FFO rose to $13.20–13.30. Saks replacement leases could turn $18M rent into ~$44M, mainly in 2027. (SEC supplemental, transcript)

• “Class-A retail resilience.” Piper Sandler pre-result: NOI/leasing/dividend execution remains strong. Risk: affluent consumer slows. Confidence: medium.
• “Rates/valuation cap upside.” Deutsche Bank pre-result Hold/$220: fundamentals are priced and $4.5B of 2H27 maturities raises refinancing drag. Flat AH response fits. Confidence: medium.

Consensus: premier-mall operations strong. Disagreement: NOI/rent compounding versus valuation/rates. Resolvers: holiday sales, Saks rent, occupancy, refinancing and 9%-yield developments.

19. AECOM (ACM)

Facts. A $337M pretax legacy construction-management charge produced reported adjusted EPS -$0.50; excluding it, EPS $1.49 beat $1.46 and EBITDA rose 5%. Backlog +13% with 1.6x book-to-burn. Underlying FY EPS/EBITDA held, but FCF fell from $400M to ~$300M; call is Aug. 11. (Release)

• “Legacy air pocket; design intact.” No same-day note; inference against broad bullish analyst baseline: record backlog and held underlying guide support normalized earnings. Risk: residual P3 exposure. Confidence: medium-high.
• “Cash hit is real.” Inference: ~$700M CM/restructuring cash use, higher leverage/interest and reduced buybacks make this more than accounting. Confidence: high.
• “Infrastructure demand, slow conversion.” Inference: positive for design consultants, caution for fixed-risk/P3 contracts. Confidence: medium.

Consensus: sound design franchise, value-destructive project event. Disagreement: isolated 2019 contract versus risk-control weakness. Resolvers: Aug. 11 Q&A, project completion, cash phasing, remaining P3 and claims.

20. Camtek (CAMT)

Facts/call. Revenue $133.2M and EPS $0.78 only modestly beat. Q3 guide $158–160M; H2 now >30% above H1. YTD orders exceed $600M, 80% advanced packaging and >20% HBM; Q4 advanced-packaging revenue is expected +70% from Q1. (SEC filing)

• “AI packaging supercycle.” Jefferies pre-result: orders, HBM/OSAT breadth, guide raise and exit margins support outgrowth through 2027. Risks: concentration, timing, logistics. Confidence: high 2026, medium 2027.
• “Strong but priced/competitive.” Matthew Prisco/Cantor pre-result Neutral: tiny reported beat, peers also guide strong AP, and shares surrendered most of +9% opening gain. Disconfirming: CAMT outperformed SOXX by >4 pp. Confidence: medium-high.
• “Order quality broadens.” Inference: OSAT/photonics/Hawk-G5 diversify beyond HBM. Confidence: medium.

Consensus: acceleration/backlog real. Disagreement: differentiated share/intensity versus AP wave already discounted. Resolvers: Q4 revenue/margins, 2027 guide, orders, DSO and competitive wins.

21. RadNet (RDNT)

Facts/call. Revenue $622.7M beat ~$610M; EPS $0.29 beat $0.18–0.20. Advanced-imaging volume +21.2%; Digital Health revenue +56.5%, AI +136%, ARR +97% to $105.5M. Imaging revenue/EBITDA/FCF guidance rose; AI ARR target >$140M was held. (Release, transcript)

• “Clean beat/raise, secular imaging.” Brian Tanquilut/Jefferies called it a solid win; volumes, record EBITDA and second raise support 2–6 quarter demand/JV growth. Risk: acquisition/capacity spending. Confidence: high facts, medium external opinion.
• “AI becomes monetizable capacity.” David MacDonald/Truist; Tanquilut/Jefferies; KeyBanc: $105.5M ARR, draft-report acceptance and breast-ultrasound opportunity support labor relief plus SaaS/reimbursement revenue. Risks: FDA/payers/Q4-loaded deployments. Confidence: medium-high.
• “Show me margins.” Andrew Cooper/Raymond James and Larry Solow/CJS: richer mix and AI delivered only 17 bp core margin expansion; Digital Health must scale toward 20%+. Confidence: high that this is the debate.

Consensus: advanced imaging and AI commercialization validated. Disagreement: speed of profit conversion. Resolvers: ARR go-lives, H2 Digital Health EBITDA, breast reimbursement, Q3 margin and final CMS site-neutral rule.

6. Cross-event themes and contradictions

1. Global inflation signals conflict. Hormuz pushed oil, gas and Treasury yields sharply higher, while China CPI/PPI showed fading energy pass-through and weak domestic demand. Near-term U.S./European inflation risk is supply-driven even as China supplies a disinflationary demand impulse.
2. Demand is easier to prove than earnings conversion. AAON, Camtek, Rocket Lab, AST SpaceMobile, RadNet, B&W and RIOT all reported strong orders/backlog/ARR/leases. Their equity outcomes hinged on margin, funding, cash burn and timing—not demand existence.
3. AI capex is broadening beyond chips. Same-day evidence reached advanced-packaging inspection (CAMT), liquid cooling (AAON), power equipment (BW), powered-land/data centers (RIOT), imaging workflow (RDNT) and workflow software (MNDY). The contradiction is that semicap shares weakened on the day even while physical-infrastructure order data stayed strong.
4. Forward narrative dominated reported beats. Barrick, AAON, monday.com, Embraer, Hims and Upwork all demonstrate that guide quality, transaction disclosure or cash economics outweighed headline EPS/revenue surprise.
5. Balance sheets are increasingly central. Rocket Lab's liquidity was ATM-funded; ASTS and Archer are spending heavily; RIOT requires project debt; BW's cash rose largely from equity; BridgeBio used preferred financing; AECOM's “one-off” charge has continuing cash effects. Capital is available, but the cost and per-share dilution are differentiators.
6. Consumer read-through is bifurcated. SPG's affluent-mall sales/leasing were strong, Ferguson still described housing/RMI as weak, JBS showed beef scarcity and consumer trade-down, and China pricing showed deficient demand. There is no single “consumer” tape.

7. Coverage audit

Calendars and source sets checked

• Macro calendars: New York Fed research calendar, Kiplinger U.S. economic calendar, Trading Economics country calendars, official statistical/central-bank calendars, and current AP/Reuters/Axios market wires.
• Primary macro sources: China's NBS CPI/PPI releases and explanation, EIA oil/SPR series, and official/government statements reproduced by AP/Axios. No official Federal Reserve event qualified.
• Earnings inventories: Kiplinger/Briefing calendar, AskTheDate, Digrin, TipRanks, MarketBeat, Investing.com/Benzinga estimate pages, company IR calendars, and SEC EDGAR filings accepted August 10.
• Primary earnings sources: every included company was cross-checked to an SEC filing or company IR release; available call transcripts/replays were checked. Price moves were cross-checked with live/historical quote feeds and should be read as snapshots where after-hours.
• Opinion sources: public same-day Reuters/AP/major financial media, company calls, public analyst-rating summaries and dated pre-result notes. A call question is labeled as a question/frame, never as an endorsement. No inaccessible paywalled note is implied as reviewed.

Borderline events excluded

• U.S. 3- and 6-month bill auctions: 3-month high rate 3.735% versus 3.750% prior; 6-month 3.830% versus 3.855%. Routine, orderly and no distinct cross-asset impact.
• Norway July CPI/PPI and Japan current-account data: economically relevant locally, but no material, separable U.S./global market move at the cutoff.
• Plug Power, Rapid7, Quantum Computing, Amentum and other sub-$10B routine reporters: reported or were scheduled, but lacked the market-cap, sector novelty or outsized verified reaction threshold used here.
• HFFG, PIII, PLBY, GENK, GETY, EVC and OPFI after-hours movers: large percentage prints appeared in thin trading, but no sufficiently broad/liquid or verified sector catalyst justified “major” treatment.
• Calendar artifact for a Cleveland Fed/Hammack appearance: no official Aug. 10 event or same-day remarks could be verified; excluded rather than inventing a Fed catalyst.

Calls/transcripts and analyst notes not yet available

• Calls scheduled Aug. 11: Alcon (8:00 a.m. ET), AECOM (8:00 a.m.), JBS (9:00 a.m.). Their Aug. 10 release facts are included; Q&A is explicitly pending.
• No public Q2 transcript/Q&A was available at cutoff for monday.com, Axsome, Archer or Upwork; no Q&A claims were invented.
• Same-day formal sell-side notes were publicly sparse across most after-close reporters. Where the report uses dated baselines (for example Jefferies/UBS on MNDY or Barclays/Morgan Stanley on BBIO), they are labeled pre-result. Analyst call questions are separated from opinions.
• Formal same-day post-result analyst notes were not public for NIQ; its available transcript/Q&A is included, and call question framing is not treated as a rating.

Material data gaps and caveats

• China released inflation over the U.S. weekend, so Monday's first-tradable China moves are full-session and confounded by Hormuz; there is no tick-clean cash reaction.
• No reliable public consensus was found for China PPI m/m. NBS did not flag revisions; that is not the same as an explicit “unrevised” statement.
• Earnings estimate aggregators sometimes mix GAAP/non-GAAP (notably ASTS, Embraer, AECOM and JBS) or map quarters differently (Ferguson). Provider-specific ranges are shown rather than a false synthetic consensus.
• After-hours prices are thin and may change before Tuesday's open. RIOT's +25%, BW's +40.5%, NIQ's +18.0%, Upwork's -20%, Hims' -5.6%, and other AH moves are cutoff snapshots.
• Public same-day opinion evidence was strongest for the two macro events and Barrick; it was sparse for many company calls. This report lowers confidence rather than manufacturing clusters.

---

Bottom line: Monday was a stagflation-risk macro session layered over an unusually broad earnings slate. The most useful common signal is that markets are no longer paying for “AI exposure,” backlog or revenue growth in isolation; they are paying for credible timing, margin conversion, financing and disclosure quality.